Statin Use Is Associated With Disseminated Superficial Actinic Porokeratosis: A Population-Based Analysis.

Authors

Dora R Goldstein, Kritin K Verma, Orson T Robertson, Kevin T Nguyen, Sahil Kapur, Daniel P Friedmann, Michelle B Tarbox

Published in

Cureus. Volume 18. Issue 6. Pages e111144. Epub Jun 19, 2026.

Abstract

Statins are lipid-lowering drugs that block 3-hydroxy-3-methylglutaryl-coenzyme A reductase to prevent atherosclerotic cardiovascular disease. While statins are generally well tolerated, they have been linked to a variety of dermatological disorders. This study investigated the relationship between statin use and disseminated superficial actinic porokeratosis (DSAP), a chronic hereditary skin condition marked by hyperkeratotic papules with characteristic ridge-like borders. Using the TriNetX database, we conducted a retrospective cohort study of 970,166 statin medication patients identified by RxNorm codes. DSAP cases were identified using diagnostic codes, and propensity score matching was used to balance demographic variables between the treatment and control groups. Among statin-treated patients, 660 (0.068%) cases of DSAP were found, compared with 478 (0.049%) cases in controls. Statin medication was linked to a significant increase in DSAP risk (RR, 1.381; 95% CI, 1.227-1.553; p=0.0001). This study finds a statistically significant correlation between statin use and DSAP, emphasizing the significance of monitoring for dermatologic side effects in statin-treated patients.

PMID:
42473507
Bibliographic data and abstract were imported from PubMed on 20 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.